<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute and early HIV infection: Clinical manifestations and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute and early HIV infection: Clinical manifestations and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute and early HIV infection: Clinical manifestations and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul E Sax, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rajesh T Gandhi, MD, FIDSA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H18410695"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute human immunodeficiency virus (HIV) infection may present as a mononucleosis type of syndrome with a constellation of nonspecific symptoms. Without a high degree of suspicion, the diagnosis can frequently be missed by clinicians. In some cases, early HIV infection may be asymptomatic.</p><p>The clinical manifestations and diagnosis of acute and early HIV will be reviewed here. The pathogenesis, epidemiology, and treatment of early HIV infection are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3752.html" rel="external">"Acute and early HIV infection: Pathogenesis and epidemiology"</a> and  <a class="medical medical_review" href="/z/d/html/3717.html" rel="external">"Acute and early HIV infection: Treatment"</a>.)</p><p class="headingAnchor" id="H28808567"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>Different terms, including acute, recent, primary, and early HIV infection, have been used in the literature to refer to variable intervals following initial infection with the virus. In this topic, we use the term "early HIV infection" to refer to the approximate six-month period following HIV acquisition. We use the term "acute HIV infection" to refer to symptomatic early infection, as this reflects common usage in clinical care.</p><p class="headingAnchor" id="H956363"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H957217"><span class="h2">Asymptomatic infection</span><span class="headingEndMark"> — </span>An estimated 10 to 60 percent of individuals with early HIV infection will not experience symptoms, although the exact proportion is difficult to estimate since patients generally come to attention because of symptoms, and thus asymptomatic infections often remain undetected. In a study of 50 acutely infected individuals who had been identified by prospective viral testing of high-risk individuals and then were followed twice weekly, almost all had at least one reported symptom or sign during the first four weeks of infection, but these were mainly short-lived, nonspecific, and unlikely to have brought the individual to clinical attention outside of a study setting [<a href="#rid1">1</a>]. Subjects complained of symptoms at only 29 percent of the biweekly study visits during this period.</p><p class="headingAnchor" id="H956370"><span class="h2">Time course</span><span class="headingEndMark"> — </span>In patients who have acute symptomatic infection, the usual time from HIV exposure to the development of symptoms is two to four weeks, although incubation periods as long as ten months have been observed [<a href="#rid2">2</a>]. In one study that evaluated viral dynamics following HIV infection, the highest frequency of symptoms and signs were observed just before peak viremia occurred, approximately two weeks after the initial detection of viral RNA [<a href="#rid1">1</a>]. It is possible that the route of acquisition and quantity of virus inoculum influence the time to peak viremia and the length of the incubation period. </p><p>Most symptoms associated with acute HIV infection are self-resolving; however, the severity and duration of symptoms vary widely from patient to patient. </p><p class="headingAnchor" id="H98516842"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>A variety of symptoms and signs may be seen in association with acute symptomatic HIV infection. This constellation of symptoms is also known as the acute retroviral syndrome. Published series consistently report that the most common findings are fever, lymphadenopathy, sore throat, rash, myalgia/arthralgia, diarrhea, weight loss, and headache  (<a class="graphic graphic_table graphicRef87682" href="/z/d/graphic/87682.html" rel="external">table 1</a>) [<a href="#rid1">1,3-7</a>]. None of these findings is specific for acute HIV infection, but certain features, especially prolonged duration of symptoms and the presence of mucocutaneous ulcers, are suggestive of the diagnosis.</p><p>Beyond these more common symptoms, a wide range of other symptoms have been described in patients with acute or early HIV infection. In one prospective study of 290 such patients, 17 percent were ill enough to require hospitalization [<a href="#rid6">6</a>]. In addition, 26 percent of patients were considered to have atypical symptomatic presentations, including opportunistic infections and central nervous system manifestations. </p><p>The presence and increased severity and duration of symptoms appear to be poor prognostic factors [<a href="#rid8">8-10</a>]. As an example, in a study of 218 female sex workers with well-documented dates of HIV seroconversion based on longitudinal screening, each additional symptom present at the time of acute infection was associated with an increasing risk of overall mortality after a median follow-up of 4.6 years [<a href="#rid10">10</a>]. Importantly, these data were collected on patients who did not have access to HIV therapy.</p><p class="headingAnchor" id="H956377"><span class="h3">Constitutional symptoms</span><span class="headingEndMark"> — </span>Fever, fatigue, and myalgias are the most common symptoms reported by patients with acute HIV infection [<a href="#rid1">1,8,11</a>]. Fever in the range of 38 to 40ºC is present in the vast majority of patients with symptomatic acute HIV infection [<a href="#rid4">4,9,12-14</a>]. In one study of 41 patients, the mean maximum reported temperature was 38.9ºC [<a href="#rid15">15</a>]. </p><p class="headingAnchor" id="H957324"><span class="h3">Adenopathy</span><span class="headingEndMark"> — </span>Nontender lymphadenopathy primarily involving the axillary, cervical, and occipital nodes is also common. Adenopathy often develops during the second week of the illness, concomitant with the emergence of a specific immune response to HIV. The nodes decrease in size following the acute presentation, but a modest degree of adenopathy tends to persist [<a href="#rid14">14</a>]. Mild hepatosplenomegaly also can occur [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H956384"><span class="h3">Oropharyngeal findings</span><span class="headingEndMark"> — </span>Sore throat is a frequent manifestation of acute HIV infection. The physical examination reveals pharyngeal edema and hyperemia, usually without tonsillar enlargement or exudate [<a href="#rid17">17,18</a>]. However, unilateral or bilateral tonsillitis has also been described [<a href="#rid6">6</a>]. </p><p>Painful mucocutaneous ulceration is one of the most distinctive manifestations of acute HIV infection. Shallow, sharply demarcated ulcers with white bases surrounded by a thin area of erythema may be found on the oral mucosa, anus, penis, or esophagus [<a href="#rid19">19</a>]. These ulcerative lesions may reflect mucocutaneous disease associated with acute HIV infection [<a href="#rid14">14</a>] or coincident sexually transmitted infections, such as herpes simplex virus, syphilis, or chancroid [<a href="#rid20">20</a>]. In one study of 10 men who have sex with men (MSM) with acute HIV infection and mucocutaneous ulceration limited to one location, the lesions occurred at a site involved in sexual activity at the time of probable transmission. (See  <a class="medical medical_review" href="/z/d/html/7595.html" rel="external">"Prevention of sexually transmitted infections"</a>.)</p><p>In another study of 16 men with acute HIV infection and odynophagia, endoscopy demonstrated esophageal ulcers 0.3 to 1.5 cm in diameter in all of the patients [<a href="#rid21">21</a>]. Tissue obtained from these ulcers in eight of the subjects revealed virus particles by electron microscopy that were morphologically consistent with HIV; in one patient HIV was cultured from the lesion. </p><p class="headingAnchor" id="H957339"><span class="h3">Rash</span><span class="headingEndMark"> — </span>A generalized rash is also a common finding in symptomatic acute HIV infection. The eruption typically occurs 48 to 72 hours after the onset of fever and persists for five to eight days. The upper thorax, collar region, and face are most often involved, although the scalp and extremities, including the palms and soles, may be affected. The lesions are characteristically small (5 to 10 mm), well-circumscribed, oval or round, pink to deeply red colored macules or maculopapules [<a href="#rid19">19</a>]. Vesicular, pustular, and urticarial eruptions have also been reported [<a href="#rid18">18,22</a>] but are not nearly as common as a maculopapular rash. Pruritus is unusual and only mild when present.</p><p>Histopathologic findings are nonspecific in the skin lesions, and biopsy of a skin lesion usually does not assist in the diagnosis of acute HIV infection. The epidermis is normal and the dermis contains a sparse lymphocytic infiltrate, mainly around vessels of the superficial plexus [<a href="#rid16">16</a>]. </p><p class="headingAnchor" id="H98516951"><span class="h3">Gastrointestinal symptoms</span><span class="headingEndMark"> — </span>Since the gastrointestinal tract is a primary target during acute infection, patients with acute HIV infection often complain of nausea, diarrhea, anorexia, and weight loss, averaging 5 kg. More serious gastrointestinal manifestations are rare and include pancreatitis and hepatitis [<a href="#rid23">23,24</a>]. </p><p class="headingAnchor" id="H956391"><span class="h3">Neurologic findings</span><span class="headingEndMark"> — </span>Headache, often described as retroorbital pain exacerbated by eye movement, frequently accompanies acute HIV infection. More serious neurologic manifestations of acute HIV infection have also been reported but are unusual [<a href="#rid6">6,25</a>].</p><p>The first severe neurologic syndrome to be recognized was aseptic meningitis, with severe headache, meningismus, photophobia, and a lymphocytic pleocytosis on cerebrospinal fluid (CSF) analysis [<a href="#rid26">26,27</a>]. In a study of 41 patients with symptomatic acute HIV infection, 10 (24 percent) had symptoms and signs suggestive of aseptic meningitis [<a href="#rid15">15</a>]. HIV was cultured from the CSF in 12 of the 24 patients who agreed to undergo lumbar puncture (a median of 51 days after HIV seroconversion). Meningoencephalitis can also occur during acute HIV infection [<a href="#rid28">28,29</a>]. </p><p>Rarely, a self-limited encephalopathy may accompany acute HIV infection. One report described two patients with fever, pronounced personality changes, confusion, and, in one case, tonic/clonic seizures, associated with seroconversion to HIV [<a href="#rid30">30</a>]. Another report described an acutely infected patient with signs of both encephalopathy and myelopathy, including lower extremity spasticity, bilateral extensor plantar reflexes, and urinary retention, which progressed to upper extremity spasticity and weakness [<a href="#rid31">31</a>].</p><p>The peripheral nervous system also may be affected by acute HIV infection. As an example, one report described two cases of Guillain-Barré syndrome occurring 1 and 20 weeks after symptomatic acute HIV [<a href="#rid32">32</a>]. Facial nerve and brachial palsies have also been noted [<a href="#rid22">22,33,34</a>].</p><p class="headingAnchor" id="H956405"><span class="h3">Other</span><span class="headingEndMark"> — </span>Apart from complaints of a dry cough, pulmonary manifestations are uncommon during acute HIV infection. There have been rare reports of pneumonitis in this setting, manifesting as cough, dyspnea, and hypoxia without evidence for other infectious etiologies [<a href="#rid35">35,36</a>]. Two of these patients had increased interstitial markings on chest radiograph. Bronchoalveolar lavage was performed in one patient and revealed a predominance of CD8+ lymphocytes.</p><p>Acute rhabdomyolysis and vasculitis are other unusual manifestations [<a href="#rid37">37,38</a>]. (See  <a class="medical medical_review" href="/z/d/html/5165.html" rel="external">"Overview of viral myositis"</a>.)</p><p class="headingAnchor" id="H956412"><span class="h2">Opportunistic infections</span><span class="headingEndMark"> — </span>Although usually associated with later stage HIV disease, opportunistic infections can rarely occur during the transient CD4 lymphopenia of early HIV infection [<a href="#rid39">39</a>]. In a study of 290 patients who were diagnosed with acute or early HIV infection at a single center over 10 years, 21 presented with an opportunistic illness [<a href="#rid6">6</a>]. </p><p>Oral and esophageal candidiasis is the opportunistic infection most often seen in these patients [<a href="#rid6">6,40,41</a>]. The factors responsible for the frequency of esophageal candidiasis during the immunosuppression of acute HIV infection are not well understood [<a href="#rid42">42</a>]. Two possibilities are that esophageal ulceration provides a local environment that promotes the growth of Candida species, and that the administration of antibiotics to empirically treat the symptoms of acute HIV may alter normal oropharyngeal flora.</p><p>Other opportunistic infections that have been reported during acute HIV infection include cytomegalovirus (CMV) infection (proctitis, colitis, and hepatitis) [<a href="#rid6">6,24</a>], <em>Pneumocystis jirovecii</em> pneumonia [<a href="#rid43">43</a>], and prolonged, severe cryptosporidiosis [<a href="#rid44">44</a>]. </p><p class="headingAnchor" id="H956419"><span class="h2">Laboratory features</span><span class="headingEndMark"> — </span>In early HIV infection, which is a period of rapid viral replication and infection of CD4 T cells, the viral RNA level is typically very high (eg, &gt;100,000 copies/mL) and the CD4 cell count can drop transiently. (See <a class="local">'HIV RNA detection'</a> below and <a class="local">'Opportunistic infections'</a> above.)</p><p>As an example, in a study of 50 acutely infected individuals, the median peak viral level was approximately 5 million copies/mL and occurred at a median of 13 days (range 6 to 18) following initial detection of viral RNA [<a href="#rid1">1</a>]. Subsequently, the viral load dropped to a median of 30,000 copies/mL between 18 and 42 days following RNA detection and remained generally stable within one log over the following year.</p><p>The leukocyte count and lymphocyte subset counts vary during the acute illness. Initially, there is a fall in the total white blood cell count. In one study, for example, the leukocyte count dropped to a low of 960/microL nine days after the onset of symptoms [<a href="#rid45">45</a>]. CD4 cell counts drop in relation to the increase in viral load, and CD8 cell counts increase. Following peak viremia, CD4 cell counts rebound and CD8 cell counts decline, but do not generally return to baseline levels. CD8 cell levels remain higher than CD4 cell levels, resulting in a persistent inversion of the normal CD4:CD8 ratio to less than 1 [<a href="#rid45">45</a>]. Atypical lymphocytes may be seen during this latter phase although at a frequency and intensity significantly less than in the classic mononucleosis syndrome caused by Epstein-Barr virus (EBV) (&lt;50 percent versus 90 percent of cases).</p><p>A positive heterophile antibody test has also been reported uncommonly during acute HIV [<a href="#rid14">14,16,18</a>]; whether this represents a false positive test or reactivation of EBV during acute HIV is not clear [<a href="#rid46">46</a>]. Regardless of the cause, the importance of this finding is that a positive heterophile antibody test does not exclude the diagnosis of acute HIV infection. </p><p>Additionally, elevations of liver enzymes, mild anemia, and thrombocytopenia have all been reported in association with early HIV infection.</p><p class="headingAnchor" id="H956440"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of acute HIV infection includes mononucleosis due to Epstein-Barr virus (EBV) or cytomegalovirus (CMV), toxoplasmosis, rubella, syphilis, disseminated gonococcal infection, viral hepatitis, and other viral infections. Certain features of new onset autoimmune diseases may also resemble the acute retroviral syndrome. A number of clinical findings help distinguish these disorders from acute HIV:</p><p class="bulletIndent1"><span class="glyph">●</span>Mucocutaneous ulceration is unusual in these other infections with the exception of syphilis and, if present, should heighten suspicion for acute HIV.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rash is uncommon in EBV mononucleosis (unless antibiotics have been administered), CMV mononucleosis, and toxoplasmosis and tends to spare the palms and soles in rubella. The rash of acute HIV infection may resemble pityriasis rosea, but marked constitutional symptoms are unusual in pityriasis [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The abrupt onset of symptoms, pharyngeal edema with little associated tonsillar exudate or hypertrophy, and diarrhea, which can be seen in acute HIV, are features that help to distinguish it from EBV mononucleosis. Both atypical lymphocytosis and a positive heterophile antibody test can occur in the setting of acute HIV; thus, these findings do not exclude the possibility of HIV. However, the number of atypical lymphocytes present is generally higher in EBV than HIV.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New onset systemic lupus erythematosus (SLE) can closely resemble acute HIV infection. However, SLE is distinguished by the presence of antinuclear antibodies.</p><p></p><p>Symptoms associated with the acute retroviral syndrome have also been observed in patients with established HIV infection who discontinued suppressive antiretroviral therapy (ART) [<a href="#rid47">47,48</a>]. In these case reports, symptoms including fever, lymphadenopathy, and rash developed in four patients 10 days to four weeks after discontinuing all antiretroviral drugs. HIV viral levels, which had been &lt;50 copies/mL in all of the patients, rose dramatically to as high as 1,000,000 copies/mL, and CD4 counts dropped appreciably. Cases of recrudescent symptomatic acute HIV have also been reported in patients treated during acute infection who have stopped treatment [<a href="#rid49">49</a>]. These situations are easily distinguished from the acute retroviral syndrome of acute HIV infection by history.</p><p class="headingAnchor" id="H18410709"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of acute or early HIV infection is established by the detection of HIV viremia in the setting of a particular HIV testing pattern (ie, negative screening immunoassay OR a positive combination antibody/antigen immunoassay with a negative antibody-only immunoassay). However, because of the increasing sensitivity of available immunoassays, an individual with acute or early HIV infection (ie, infected within the prior six months) may already have completely reactive immunoassays (eg, both the combination antibody/antigen immunoassay and the antibody-only immunoassay) in addition to detectable viremia. In such cases, the timing of infection, and thus the diagnosis of acute or early versus established infection, must be inferred from clinical presentation (eg, symptoms consistent with acute retroviral syndrome at presentation or recognized in hindsight or a very high viral RNA level), exposure history, and any available past serological testing.</p><p>When the possibility of acute or early HIV infection is being considered based on clinical suspicion (see <a class="local">'Clinical suspicion'</a> below), we perform the most sensitive immunoassay available (ideally, a combination antigen/antibody immunoassay) in addition to an HIV virologic (viral load) test. (See <a class="local">'Diagnostic algorithm'</a> below.)</p><p>Because of the increasing availability of HIV screening tests that significantly shorten the time from HIV acquisition to a positive test and recommendations to use specific screening algorithms that are more sensitive for early infection [<a href="#rid50">50</a>], more patients with acute or early HIV are being diagnosed on routine screening. (See <a class="local">'Detection of early infection through routine screening'</a> below and  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection", section on 'Testing algorithm'</a>.)</p><p>Given the increasing data supporting individual and public health benefits for antiretroviral therapy (ART) during acute and early infection instead of later in the course of the disease, newly-diagnosed patients should be referred promptly to an appropriate specialist to review treatment options. (See  <a class="medical medical_review" href="/z/d/html/3717.html" rel="external">"Acute and early HIV infection: Treatment", section on 'Rationale for initiation of ART in early infection'</a>.)</p><p class="headingAnchor" id="H98516166"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>Given the wide range of symptoms associated with acute HIV infection, clinicians should have a low threshold to suspect it. In particular, the possibility of acute HIV infection should be considered in patients who present with the more typical signs and symptoms, including an ill-defined febrile illness, heterophile-negative mononucleosis-like syndrome, heterophile positive mononucleosis in an unusual host (for example, an older adult patient), and/or aseptic meningitis. Certain clinical features, such as a rash, mucocutaneous ulcers, diarrhea, or lymphadenopathy, should heighten the suspicion for HIV infection. (See <a class="local">'Clinical features'</a> above.)</p><p>Although all patients should be questioned about HIV risk behaviors, including sexual activity and injection drug use, patients may be reluctant to disclose this information or may not perceive their behavior as high risk. As an example, we have seen several men who acquired HIV through receptive oral sex and expressed surprise that this was a mode of HIV transmission (see  <a class="medical medical_review" href="/z/d/html/3768.html" rel="external">"Management of nonoccupational exposures to HIV and hepatitis B and C in adults", section on 'Exposure to HIV'</a>). Thus, the absence of elicited risk factors should not preclude the possibility of HIV infection.</p><p>Early HIV infection should also be considered in patients who have had a recent high-risk exposure or those who have had a recent sexually transmitted infection (particularly syphilis), regardless of the presence of symptoms or signs. Certain patients who have had a very recent high-risk exposure (ie, within 72 hours) may be candidates for post-exposure prophylaxis (PEP) against HIV. The evaluation and management of such patients are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3768.html" rel="external">"Management of nonoccupational exposures to HIV and hepatitis B and C in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3764.html" rel="external">"Management of health care personnel exposed to HIV"</a>.)</p><p class="headingAnchor" id="H958156"><span class="h2">Diagnostic algorithm</span><span class="headingEndMark"> — </span>When the possibility of acute or early HIV infection is being considered, we perform the most sensitive diagnostic tests available, such as an HIV virologic (viral load) test. We favor using an RT-PCR-based viral load test, if available. We also send a combination antigen/antibody test in addition to an HIV virologic (viral load) test, as these tests, if negative in the context of a detectable HIV viral load, strongly suggest early HIV infection. Note that with current assays, a positive HIV virologic test is generally diagnostic of HIV infection, as false positive results on these tests have become quite rare. Special considerations for patients with a recent exposure and for those taking pre-exposure prophylaxis (PrEP) are discussed below. (See <a class="local">'Considerations for specific populations'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Negative antigen/antibody test and negative virologic test</strong> – A negative HIV antigen/antibody test and negative virologic test strongly suggest that HIV infection has not been acquired. In the case of very recent high-risk exposures when HIV transmission remains a concern, repeat testing in one to two weeks (especially if symptoms of acute HIV develop) is warranted. (See <a class="local">'Very recent exposure'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Negative antigen/antibody test and detectable viral load</strong> – A negative HIV antigen/antibody test and a detectable viral load suggest early HIV infection. In most patients, HIV RNA levels are markedly elevated; however, in some cases the viral load may be low. As an example, this may occur in patients receiving PrEP since they may have partial suppression due to the antiretroviral agents they are receiving. (See <a class="local">'Patients taking pre-exposure prophylaxis'</a> below.)</p><p></p><p class="bulletIndent1">On rare occasion, a low RNA level (eg, &lt;100 copies/mL) may represent a false positive viral test. In this setting, the viral load test should be repeated on a new blood specimen; a second positive virologic test suggests HIV infection. Some experts use a higher threshold when considering a false positive viral load [<a href="#rid51">51</a>], but we favor being more conservative, especially in patients with risk factors for HIV infection, given the specificity of current assays. (See <a class="local">'HIV RNA detection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Positive antigen/antibody test and detectable viral load</strong> – A positive antigen/antibody test and positive virologic test can be seen in either early or established HIV infection. A positive antigen/antibody test should prompt a second, antibody-only immunoassay (preferably the HIV-1/HIV-2 differentiation immunoassay) if not already performed. A negative result on this second test with a positive virologic test supports the diagnosis of early HIV infection. However, a positive result on the second immunoassay does not exclude the possibility of recent infection and seroconversion. In such cases, the distinction between early and established infection must be inferred from clinical presentation (eg, symptoms consistent with acute retroviral syndrome at presentation or recognized in hindsight or a very high viral RNA level), exposure history, and any available past serological testing (eg, a negative serological test within the prior six months).</p><p></p><p>This diagnostic algorithm for suspected acute HIV infection is distinct from general screening algorithms that include an immunoassay followed by a confirmatory immunoassay of a second type if the first is positive, with HIV RNA testing reserved for discrepant results between the two immunoassays. The major difference is the use of the virologic test at the same time as the screening immunoassay. (See <a class="local">'Detection of early infection through routine screening'</a> below and  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection"</a>.)</p><p class="headingAnchor" id="H986011805"><span class="h2">Detection of early infection through routine screening</span><span class="headingEndMark"> — </span>Since many guidelines now recommend universal screening for HIV infection, new HIV diagnoses, including those of early infection, may be made among patients in whom HIV infection was not initially suspected. </p><p>In the United States, the recommended algorithm for screening involves an initial fourth generation combined antigen/antibody immunoassay with a confirmatory antibody-only HIV-1/HIV-2 differentiation immunoassay followed by HIV viral testing if there is a discrepancy  (<a class="graphic graphic_algorithm graphicRef91270" href="/z/d/graphic/91270.html" rel="external">algorithm 1</a>) [<a href="#rid50">50</a>]. In this algorithm, acute or early HIV is diagnosed when the initial immunoassay is reactive, the second immunoassay is nonreactive, and the viral test detects HIV RNA repeatedly or at a high level. (See  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection", section on 'Testing algorithm'</a>.) </p><p>This algorithm is more sensitive for detecting acute and early HIV infection than the previous algorithm, which involved following a reactive screening immunoassay with a Western blot test. As an example, in a study of 99 patients who had a reactive combination antibody and antigen immunoassay on screening followed by a nonreactive second immunoassay, RNA testing was positive in 55 individuals, thus making the diagnosis of early infection [<a href="#rid52">52</a>]. Of these patients with early infection, 27 also underwent Western blot testing, of whom 15 (56 percent) had a negative test and thus may have otherwise had missed diagnoses. </p><p>Of note, while this algorithm is more likely to detect some cases of early HIV infection during routine screening, if acute or early HIV infection is suspected (eg, based on the presence of symptoms or recent exposures), we continue to favor performing a sensitive immunoassay and virologic test at the same time. (See <a class="local">'Diagnostic algorithm'</a> above.)</p><p>Some laboratories may still employ Western blot testing to confirm an initial reactive immunoassay. Detecting early HIV with this algorithm requires checking a viral RNA test if the Western blot is negative or indeterminate. In such cases, a reactive immunoassay followed by a negative or indeterminate Western blot followed by a positive viral RNA test is most likely indicative of early HIV infection. Thus, a reactive immunoassay followed by a negative or indeterminate Western blot should not be erroneously interpreted as a negative screening pattern for HIV without further testing. </p><p class="headingAnchor" id="H1294427400"><span class="h2">Clinical relevance of early detection</span><span class="headingEndMark"> — </span>Diagnosis of acute HIV is important, since prompt initiation of ART reduces the likelihood of HIV transmission to others and can reduce the size of the latent HIV reservoir, potentially making patients eligible for future investigative HIV eradication strategies. Early ART also can improve symptoms related to acute HIV infection. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3717.html" rel="external">"Acute and early HIV infection: Treatment", section on 'Rationale for initiation of ART in early infection'</a>.)</p><p class="headingAnchor" id="H98517126"><span class="h2">Considerations for specific populations</span></p><p class="headingAnchor" id="H98517134"><span class="h3">Very recent exposure</span><span class="headingEndMark"> — </span>Detectable viremia does not develop until approximately 10 to 15 days after infection, and even the most sensitive immunoassays do not become positive until five days after that  (<a class="graphic graphic_table graphicRef87673" href="/z/d/graphic/87673.html" rel="external">table 2</a>). Thus, if exposure occurred during this window, the diagnosis of HIV infection may be missed. If initial immunoassay and virologic tests are negative and clinical suspicion for recent HIV exposure is high, we repeat testing one to two weeks later. </p><p class="headingAnchor" id="H3087101260"><span class="h3">Patients taking pre-exposure prophylaxis</span><span class="headingEndMark"> — </span>Some patients who are taking pre-exposure prophylaxis (PrEP) will acquire HIV. Such patients may have ambiguous HIV test results. As an example, patients with acute HIV typically have high viral loads, but those on PrEP may have low viral loads because of the antiviral activity of the PrEP regimen. </p><p>In general, any detectable viral load is suggestive of new HIV infection (particularly in populations with risk factors for HIV transmission), since current assays are unlikely to have false positives. However, in persons with a very low HIV RNA (eg, &lt;100 copies/mL), the diagnosis should be confirmed before initiating ART [<a href="#rid51">51</a>]. By contrast, in those with a higher, yet still low HIV RNA level (eg, 100 to 3000 copies/mL), it is reasonable to repeat the viral load for confirmation but initiate a three-drug ART regimen pending the results. If ART was initiated before confirmatory testing is performed, DNA testing may be helpful. (See  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection", section on 'Viral detection'</a>.)</p><p>A more detailed discussion of how to evaluate HIV test results in patients receiving PrEP is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis", section on 'Persons with a positive HIV test'</a>.)</p><p class="headingAnchor" id="H986011160"><span class="h2">Diagnostic test performance in early HIV infection</span></p><p class="headingAnchor" id="H986011167"><span class="h3">HIV RNA detection</span><span class="headingEndMark"> — </span>Early HIV infection is characterized by markedly elevated HIV RNA levels, easily detectable with the HIV RNA (viral load) assays commonly used for monitoring of HIV disease. Our preferred test for HIV RNA detection in the evaluation for early HIV infection is the reverse transcriptase-polymerase chain reaction (RT-PCR) test because of its superior performance to the branch DNA (bDNA) technique. Although not approved by the US Food and Drug Administration (FDA) for this indication, the RT-PCR test is widely available for HIV disease monitoring and is highly sensitive and specific. A false positive test should be ruled out if the viral load is low (eg, &lt;100 copies/mL) in the setting of suspected early HIV infection [<a href="#rid53">53,54</a>]. A repeat sample should be drawn in this setting since a second positive viral load (especially if higher) suggests a true positive result [<a href="#rid55">55</a>], as would subsequent seroconversion. (See <a class="local">'Diagnostic algorithm'</a> above.)</p><p>In a study of 436 patients with symptoms consistent with acute HIV infection, all of the 54 patients diagnosed with acute HIV had RNA levels &gt;100,000 copies/mL [<a href="#rid5">5</a>]. Although false-positive detection of HIV RNA occurred in 8 of 303 (2.6 percent) patients without HIV infection, all of the false-positives had HIV RNA levels &lt;2000 copies/mL, making them easily distinguishable from the true positives whose values were much higher. Furthermore, all of the false positives occurred with bDNA rather than RT-PCR viral load testing; bDNA testing has subsequently become less widely used. In a separate study of 258 symptomatic patients evaluated for acute HIV infection, RT-PCR based testing also had a lower false positive rate than bDNA tests (3 versus 5 percent) [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/z/d/html/3743.html" rel="external">"Techniques and interpretation of HIV-1 RNA quantitation", section on 'Laboratory methods for quantitation of HIV-1 RNA'</a>.)</p><p>A qualitative nucleic acid test (NAT) based on transcription mediated amplification is an additional sensitive method to detect acute HIV viremia in patients who are antibody-negative [<a href="#rid57">57,58</a>]. The main utility of NAT is for large population screening (such as blood donor screening), which is generally performed on pooled specimens because of the cost of the test.</p><p class="headingAnchor" id="H986011219"><span class="h3">HIV antigen detection</span><span class="headingEndMark"> — </span>The p24 antigen is a viral core protein that appears in the blood as the viral RNA level rises following HIV infection [<a href="#rid59">59,60</a>]. Although earlier assays to detect p24 antigen were considerably less sensitive than viral RNA testing, subsequent assays have better diagnostic performance, with a sensitivity range of 89 to nearly 100 percent compared to RNA detection [<a href="#rid61">61,62</a>]. This assay detects a level of antigen that approximately corresponds to an HIV RNA level of 30,000 to 50,000 copies/mL and becomes positive approximately five to seven days following the detection of viral RNA [<a href="#rid63">63-65</a>]. </p><p>The p24 antigen test is also available as combination HIV antibody/p24 antigen tests that turn positive with detection of either the antigen or the antibody and shortens the window period between HIV acquisition and a positive test compared with antibody only tests. Nevertheless, combination immunoassays remain less sensitive than nucleic acid based tests for acute HIV infection in clinical settings [<a href="#rid66">66,67</a>]. As an example, in a study comparing a fourth generation combination test (Architect) with pooled HIV RNA testing among 134 patients with acute HIV infection, both were highly specific and the combination test was less costly, but it was also less sensitive (80 versus 98 percent with pooled RNA testing) [<a href="#rid67">67</a>]. This highlights the importance of HIV viral level testing when acute or early infection is suspected. (See <a class="local">'Diagnostic algorithm'</a> above.)</p><p>Rapid combination antigen/antibody tests do not appear to be quite as sensitive as the standard combination test used in laboratories [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection", section on 'Combination HIV antigen and antibody tests'</a>.)</p><p class="headingAnchor" id="H986011225"><span class="h3">Serologic studies</span><span class="headingEndMark"> — </span>After infection with HIV, the time at which antibodies against HIV antigens can be detected in the serum depends upon the sensitivity of the serologic test  (<a class="graphic graphic_table graphicRef87673" href="/z/d/graphic/87673.html" rel="external">table 2</a>). Thus, depending on the time since infection and the sensitivity of the immunoassay test used, patients with acute or early HIV infection may have either a negative or reactive immunoassay. (See  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection"</a>.)</p><p>Very early treatment for acute HIV infection can lead to abrogation of HIV antibody responses [<a href="#rid69">69,70</a>]. As an example, in a study of 150 patients with acute HIV infection treated with ART, three patients did not develop a fully evolved antibody response and/or demonstrated evidence of seroreversion after successful HIV RNA suppression [<a href="#rid69">69</a>]. It has been postulated that maturation of the antibody response can be thwarted by rapid HIV RNA suppression early in the course of disease [<a href="#rid71">71</a>]. It is critical that clinicians and patients understand that seroreversion does not indicate viral eradication [<a href="#rid70">70,72</a>].</p><p class="headingAnchor" id="H18410737"><span class="h1">ADDITIONAL EVALUATION</span></p><p class="headingAnchor" id="H98517319"><span class="h2">Drug resistance testing</span><span class="headingEndMark"> — </span>For all patients with newly diagnosed HIV infection (including those with early HIV), drug resistance testing should be performed after the initial diagnosis has been established [<a href="#rid51">51,73</a>]. In studies of patients with acute and early HIV infection, about 15 to 20 percent of patients were infected with an isolate harboring at least one drug resistance mutation [<a href="#rid74">74-76</a>]. The presence of mutations in transmitted strains is strongly influenced by antiretroviral drug use patterns in the source. Mutations conferring resistance to non-nucleoside reverse transcriptase inhibitors are more common than protease inhibitor and integrase inhibitor resistance mutations. (See  <a class="medical medical_review" href="/z/d/html/3752.html" rel="external">"Acute and early HIV infection: Pathogenesis and epidemiology"</a>.)</p><p>In this setting, genotype resistance testing is preferred over phenotype testing because of its lower cost, faster turnaround time (approximately one versus three to four weeks), and its greater sensitivity for mixtures of resistant and wild-type virus. The interpretation of results of resistance testing is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3769.html" rel="external">"Overview of HIV drug resistance testing assays"</a> and  <a class="medical medical_review" href="/z/d/html/3772.html" rel="external">"Interpretation of HIV drug resistance testing"</a>.) </p><p class="headingAnchor" id="H956360"><span class="h2">Screening for coinfections and prior exposures</span><span class="headingEndMark"> — </span>All patients with newly diagnosed HIV infection should also undergo testing for other sexually transmitted infections. (See  <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">"Screening for sexually transmitted infections", section on 'Patients with HIV infection'</a>.)</p><p>Evaluation for exposure to other chronic infections, as performed in patients diagnosed with chronic HIV infection, is also indicated to establish the risk of possible future reactivation or need for vaccination. (See  <a class="medical medical_review" href="/z/d/html/3741.html" rel="external">"Initial evaluation of adults with HIV", section on 'Screening for coinfections'</a> and  <a class="medical medical_review" href="/z/d/html/3741.html" rel="external">"Initial evaluation of adults with HIV", section on 'Sexually transmitted infections'</a>.)</p><p class="headingAnchor" id="H3464636"><span class="h1">PUBLIC HEALTH IMPLICATIONS</span><span class="headingEndMark"> — </span>Establishing the diagnosis of early HIV infection is clearly important from the public health perspective. Patients are typically highly infectious during early HIV due to an enormous viral burden in blood and genital secretions (with a general range of serum RNA levels 100,000 to greater than one million copies/mL compared with 30,000 to 50,000 copies/mL in chronic infection without treatment) [<a href="#rid77">77-79</a>]. Moreover, such patients may be unaware that they are infected and continue to engage in risky sexual activity and needle sharing, putting others at risk. In one analysis of recently infected men who have sex with men (MSM), the rate of transmission during early infection was 9 to 15-fold greater than the transmission risk during chronic infection [<a href="#rid80">80</a>]. Similarly, in some settings, transmission from acutely infected individuals is estimated to account for the majority of new HIV infections [<a href="#rid81">81-83</a>]. Pregnant women who are unaware of their acute infection can transmit HIV perinatally unless a timely diagnosis is made and antiretroviral therapy (ART) is initiated [<a href="#rid84">84</a>].</p><p>Nevertheless, the diagnosis of acute or early HIV infection is infrequently made in clinical practice. In a case series from Seattle, for example, the diagnosis of HIV infection was considered in only 5 of 19 patients (26 percent) with acute retroviral syndrome who sought care from their primary care clinicians, emergency departments, and walk-in clinics [<a href="#rid15">15</a>]. This finding was especially surprising since these patients were enrolled in a surveillance program for HIV.</p><p>There are several reasons why acute and early HIV infection is so infrequently diagnosed:</p><p class="bulletIndent1"><span class="glyph">●</span>The symptoms, especially in mild cases, are nonspecific and resolve spontaneously without treatment. Also, many patients may be asymptomatic. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinicians may be uncomfortable asking questions about sexual exposure or intravenous drug use, especially with patients whom they see infrequently, such as young, previously healthy individuals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary care clinicians may not be aware of high-risk behavior even in patients they know well. Such patients often choose to undergo counseling and serial serologic testing at an anonymous clinic rather than to discuss risk behaviors with their primary care provider.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients may not perceive themselves to be at risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinicians and patients may assume continued validity of a previously negative HIV test, even in high-risk patients.</p><p></p><p>These issues highlight the importance of maintaining a high degree of suspicion in considering the possibility of acute HIV infection in patients with ill-defined febrile illnesses regardless of apparent risk factors. (See <a class="local">'Clinical suspicion'</a> above.)</p><p>All patients with suspected or confirmed acute or early HIV infection should be counseled to adopt behaviors that guard against HIV transmission, including consistent and correct condom use and avoidance of sharing injection drug use equipment. </p><p class="headingAnchor" id="H1406185783"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111622.html" rel="external">"Society guideline links: HIV screening and diagnostic testing"</a>.)</p><p class="headingAnchor" id="H18410843"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – In this topic, we use the term "early HIV infection" to refer to the approximate six-month period following HIV acquisition. We use the term "acute HIV infection" to refer to symptomatic early infection. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Signs and symptoms</strong> – A variety of symptoms and signs may be seen in association with acute HIV infection, known as the acute retroviral syndrome. The most common findings are fever, lymphadenopathy, sore throat, rash, myalgia/arthralgia, and headache. When it occurs, painful mucocutaneous ulceration is one of the most distinctive manifestations of acute HIV infection. Aseptic meningitis and meningoencephalitis have also been reported. Some patients with early HIV infection may have no or only very mild symptoms  (<a class="graphic graphic_table graphicRef87682" href="/z/d/graphic/87682.html" rel="external">table 1</a>). (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Viral load and CD4 count</strong> – In early HIV infection, the viral RNA level is typically very high (eg, &gt;100,000 copies/mL) and the CD4 cell count can drop transiently. Opportunistic infections can rarely occur during this transient CD4 lymphopenia. (See <a class="local">'Laboratory features'</a> above and <a class="local">'Opportunistic infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical suspicion</strong> – The diagnosis of acute HIV infection requires a high level of clinical suspicion and should be considered in patients who present with consistent signs and symptoms, including an ill-defined febrile illness, and/or aseptic meningitis. Early HIV infection should also be considered in patients who have had a recent high-risk exposure or those who have had a recent sexually transmitted infection (particularly syphilis), regardless of the presence of symptoms or signs. (See <a class="local">'Clinical suspicion'</a> above.)</p><p></p><p class="bulletIndent2">The differential diagnosis of acute HIV infection includes mononucleosis due to Epstein-Barr virus (EBV) or cytomegalovirus (CMV), toxoplasmosis, rubella, disseminated gonococcal infection, syphilis, viral hepatitis, and other viral syndromes. Certain features of new onset autoimmune diseases may also resemble the acute retroviral syndrome. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnostic testing</strong> – When the possibility of acute or early HIV infection is being considered, we perform the most sensitive diagnostic tests available, such as an HIV virologic (viral load) test. We also send a combination antigen/antibody test in addition to an HIV viral load test; a negative antigen/antibody test in the context of a detectable HIV viral load strongly suggests early HIV infection. On rare occasion, a very low viral RNA (eg, &lt;100 copies/mL) may represent a false positive test and should be repeated. (See <a class="local">'Diagnostic algorithm'</a> above.)</p><p></p><p class="bulletIndent2">Some patients infected with HIV within the previous six months will have already undergone seroconversion and thus have completely reactive immunoassays (eg, both the combination antibody/antigen immunoassay and the antibody-only immunoassay) and a positive virologic test  (<a class="graphic graphic_table graphicRef87673" href="/z/d/graphic/87673.html" rel="external">table 2</a>). In these situations, the timing of infection and thus the diagnosis of early HIV infection can be presumptively made on the basis of clinical presentation (eg, earlier symptoms consistent with acute retroviral syndrome recognized in hindsight or a very high viral RNA level), exposure history, and any available past serological testing. (See <a class="local">'Diagnostic algorithm'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of drug resistance testing</strong> – Drug resistance testing should be performed after the initial diagnosis of HIV infection. Infection with a virus that harbors at least one drug-resistant mutation is estimated to occur in up to 20 percent of newly infected patients. (See <a class="local">'Additional evaluation'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of persons who are newly diagnosed with HIV </strong>– Newly-diagnosed patients should be started on antiretroviral therapy (ART) as soon as possible. In some cases, ART can be started on the same day as diagnosis. Prompt initiation of ART can reduce the size of the latent HIV reservoir, improve symptoms related to acute HIV infection, and reduce the likelihood of transmitting HIV to others. (See  <a class="medical medical_review" href="/z/d/html/3717.html" rel="external">"Acute and early HIV infection: Treatment", section on 'Rationale for initiation of ART in early infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient counseling</strong> – All patients with suspected or confirmed acute or early HIV infection should be counseled to adopt behaviors that guard against HIV transmission, including consistent and correct condom use and avoidance of sharing injection drug use equipment. (See <a class="local">'Public health implications'</a> above.) </p><p></p><p class="headingAnchor" id="H1269897181"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Robb ML, Eller LA, Kibuuka H, et al. Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. N Engl J Med 2016; 374:2120.</a></li><li><a class="nounderline abstract_t">Ridzon R, Gallagher K, Ciesielski C, et al. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med 1997; 336:919.</a></li><li><a class="nounderline abstract_t">Kared H, Lelièvre JD, Donkova-Petrini V, et al. HIV-specific regulatory T cells are associated with higher CD4 cell counts in primary infection. AIDS 2008; 22:2451.</a></li><li><a class="nounderline abstract_t">Niu MT, Stein DS, Schnittman SM. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis 1993; 168:1490.</a></li><li><a class="nounderline abstract_t">Daar ES, Little S, Pitt J, et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med 2001; 134:25.</a></li><li><a class="nounderline abstract_t">Braun DL, Kouyos RD, Balmer B, et al. Frequency and Spectrum of Unexpected Clinical Manifestations of Primary HIV-1 Infection. Clin Infect Dis 2015; 61:1013.</a></li><li><a class="nounderline abstract_t">Crowell TA, Colby DJ, Pinyakorn S, et al. Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments. Clin Infect Dis 2018; 66:1540.</a></li><li><a class="nounderline abstract_t">Daar ES, Pilcher CD, Hecht FM. Clinical presentation and diagnosis of primary HIV-1 infection. Curr Opin HIV AIDS 2008; 3:10.</a></li><li><a class="nounderline abstract_t">Kelley CF, Barbour JD, Hecht FM. The relation between symptoms, viral load, and viral load set point in primary HIV infection. J Acquir Immune Defic Syndr 2007; 45:445.</a></li><li><a class="nounderline abstract_t">Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 2006; 42:1333.</a></li><li><a class="nounderline abstract_t">McKellar MS, Cope AB, Gay CL, et al. Acute HIV-1 infection in the Southeastern United States: a cohort study. AIDS Res Hum Retroviruses 2013; 29:121.</a></li><li><a class="nounderline abstract_t">Quinn TC. Acute primary HIV infection. JAMA 1997; 278:58.</a></li><li><a class="nounderline abstract_t">Pedersen C, Lindhardt BO, Jensen BL, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ 1989; 299:154.</a></li><li><a class="nounderline abstract_t">Gaines H, von Sydow M, Pehrson PO, Lundbegh P. Clinical picture of primary HIV infection presenting as a glandular-fever-like illness. BMJ 1988; 297:1363.</a></li><li><a class="nounderline abstract_t">Schacker T, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257.</a></li><li><a class="nounderline abstract_t">Tindall B, Cooper DA. Primary HIV infection: host responses and intervention strategies. AIDS 1991; 5:1.</a></li><li><a class="nounderline abstract_t">Valle SL. Febrile pharyngitis as the primary sign of HIV infection in a cluster of cases linked by sexual contact. Scand J Infect Dis 1987; 19:13.</a></li><li><a class="nounderline abstract_t">de Jong MD, Hulsebosch HJ, Lange JM. Clinical, virological and immunological features of primary HIV-1 infection. Genitourin Med 1991; 67:367.</a></li><li><a class="nounderline abstract_t">Lapins J, Gaines H, Lindbäck S, et al. Skin and mucosal characteristics of symptomatic primary HIV-1 infection. AIDS Patient Care STDS 1997; 11:67.</a></li><li><a class="nounderline abstract_t">Stamm WE, Handsfield HH, Rompalo AM, et al. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 1988; 260:1429.</a></li><li><a class="nounderline abstract_t">Rabeneck L, Popovic M, Gartner S, et al. Acute HIV infection presenting with painful swallowing and esophageal ulcers. JAMA 1990; 263:2318.</a></li><li><a class="nounderline abstract_t">Calabrese LH, Proffitt MR, Levin KH, et al. Acute infection with the human immunodeficiency virus (HIV) associated with acute brachial neuritis and exanthematous rash. Ann Intern Med 1987; 107:849.</a></li><li><a class="nounderline abstract_t">Rizzardi GP, Tambussi G, Lazzarin A. Acute pancreatitis during primary HIV-1 infection. N Engl J Med 1997; 336:1836.</a></li><li><a class="nounderline abstract_t">Molina JM, Welker Y, Ferchal F, et al. Hepatitis associated with primary HIV infection. Gastroenterology 1992; 102:739.</a></li><li><a class="nounderline abstract_t">Meersseman W, Van Laethem K, Lagrou K, et al. Fatal brain necrosis in primary HIV infection. Lancet 2005; 366:866.</a></li><li><a class="nounderline abstract_t">Ho DD, Sarngadharan MG, Resnick L, et al. Primary human T-lymphotropic virus type III infection. Ann Intern Med 1985; 103:880.</a></li><li><a class="nounderline abstract_t">Ho DD, Rota TR, Schooley RT, et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med 1985; 313:1493.</a></li><li><a class="nounderline abstract_t">Ambrosioni J, Artigues F, Nicolás D, et al. Neurological involvement in patients with acute/recent HIV-1 infection. A case-control study. J Neurovirol 2017; 23:679.</a></li><li><a class="nounderline abstract_t">Andrade RM, Torriani FJ, Ellis RJ. Acute HIV infection presenting as fulminant meningoencephalitis with massive CSF viral replication. Neurol Clin Pract 2014; 4:256.</a></li><li><a class="nounderline abstract_t">Carne CA, Tedder RS, Smith A, et al. Acute encephalopathy coincident with seroconversion for anti-HTLV-III. Lancet 1985; 2:1206.</a></li><li><a class="nounderline abstract_t">Denning DW, Anderson J, Rudge P, Smith H. Acute myelopathy associated with primary infection with human immunodeficiency virus. Br Med J (Clin Res Ed) 1987; 294:143.</a></li><li><a class="nounderline abstract_t">Hagberg L, Malmvall BE, Svennerholm L, et al. Guillain-Barré syndrome as an early manifestation of HIV central nervous system infection. Scand J Infect Dis 1986; 18:591.</a></li><li><a class="nounderline abstract_t">Parry GJ. Peripheral neuropathies associated with human immunodeficiency virus infection. Ann Neurol 1988; 23 Suppl:S49.</a></li><li><a class="nounderline abstract_t">Piette AM, Tusseau F, Vignon D, et al. Acute neuropathy coincident with seroconversion for anti-LAV/HTLV-III. Lancet 1986; 1:852.</a></li><li><a class="nounderline abstract_t">Ong EL, Mandal BK. Primary HIV-I infection associated with pneumonitis. Postgrad Med J 1991; 67:579.</a></li><li><a class="nounderline abstract_t">Longworth DL, Spech TJ, Ahmad M, et al. Lymphocytic alveolitis in primary HIV infection. Cleve Clin J Med 1990; 57:379.</a></li><li><a class="nounderline abstract_t">Mahé A, Bruet A, Chabin E, Fendler JP. Acute rhabdomyolysis coincident with primary HIV-1 infection. Lancet 1989; 2:1454.</a></li><li><a class="nounderline abstract_t">Bernard E, Dellamonica P, Michiels JF, et al. Heparine-like anticoagulant vasculitis associated with severe primary infection by HIV. AIDS 1990; 4:932.</a></li><li><a class="nounderline abstract_t">Gupta KK. Acute immunosuppression with HIV seroconversion. N Engl J Med 1993; 328:288.</a></li><li><a class="nounderline abstract_t">Cilla G, Perez Trallero E, Furundarena JR, et al. Esophageal candidiasis and immunodeficiency associated with acute HIV infection. AIDS 1988; 2:399.</a></li><li><a class="nounderline abstract_t">Isaksson B, Albert J, Chiodi F, et al. AIDS two months after primary human immunodeficiency virus infection. J Infect Dis 1988; 158:866.</a></li><li><a class="nounderline abstract_t">Tindall B, Hing M, Edwards P, et al. Severe clinical manifestations of primary HIV infection. AIDS 1989; 3:747.</a></li><li><a class="nounderline abstract_t">Vento S, Di Perri G, Garofano T, et al. Pneumocystis carinii pneumonia during primary HIV-1 infection. Lancet 1993; 342:24.</a></li><li><a class="nounderline abstract_t">Moss PJ, Read RC, Kudesia G, McKendrick MW. Prolonged cryptosporidiosis during primary HIV infection. J Infect 1995; 30:51.</a></li><li><a class="nounderline abstract_t">Cooper DA, Tindall B, Wilson EJ, et al. Characterization of T lymphocyte responses during primary infection with human immunodeficiency virus. J Infect Dis 1988; 157:889.</a></li><li><a class="nounderline abstract_t">Vidrih JA, Walensky RP, Sax PE, Freedberg KA. Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection. Am J Med 2001; 111:192.</a></li><li><a class="nounderline abstract_t">Colven R, Harrington RD, Spach DH, et al. Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection. Ann Intern Med 2000; 133:430.</a></li><li><a class="nounderline abstract_t">Kilby JM, Goepfert PA, Miller AP, et al. Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report. Ann Intern Med 2000; 133:435.</a></li><li><a class="nounderline abstract_t">Daar ES, Bai J, Hausner MA, et al. Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion. Ann Intern Med 1998; 128:827.</a></li><li class="breakAll">http://www.cdc.gov/hiv/pdf/HIVtestingAlgorithmRecommendation-Final.pdf (Accessed on June 30, 2014).</li><li class="breakAll">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on April 18, 2022).</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm - United States, 2011-2013. MMWR Morb Mortal Wkly Rep 2013; 62:489.</a></li><li><a class="nounderline abstract_t">Rich JD, Merriman NA, Mylonakis E, et al. Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series. Ann Intern Med 1999; 130:37.</a></li><li><a class="nounderline abstract_t">Schwartz DH, Laeyendecker OB, Arango-Jaramillo S, et al. Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR. Lancet 1997; 350:256.</a></li><li><a class="nounderline abstract_t">Stekler J, Maenza J, Stevens CE, et al. Screening for acute HIV infection: lessons learned. Clin Infect Dis 2007; 44:459.</a></li><li><a class="nounderline abstract_t">Hecht FM, Busch MP, Rawal B, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002; 16:1119.</a></li><li><a class="nounderline abstract_t">Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med 2005; 352:1873.</a></li><li><a class="nounderline abstract_t">Patel P, Mackellar D, Simmons P, et al. Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008. Arch Intern Med 2010; 170:66.</a></li><li><a class="nounderline abstract_t">Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. J Infect Dis 2010; 202 Suppl 2:S270.</a></li><li><a class="nounderline abstract_t">Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871.</a></li><li><a class="nounderline abstract_t">Pandori MW, Hackett J Jr, Louie B, et al. Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J Clin Microbiol 2009; 47:2639.</a></li><li><a class="nounderline abstract_t">Chavez P, Wesolowski L, Patel P, et al. Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay. J Clin Virol 2011; 52 Suppl 1:S51.</a></li><li><a class="nounderline abstract_t">Owen SM. Testing for acute HIV infection: implications for treatment as prevention. Curr Opin HIV AIDS 2012; 7:125.</a></li><li><a class="nounderline abstract_t">Branson BM, Stekler JD. Detection of acute HIV infection: we can't close the window. J Infect Dis 2012; 205:521.</a></li><li><a class="nounderline abstract_t">Delaney KP, Hanson DL, Masciotra S, et al. Time Until Emergence of HIV Test Reactivity Following Infection With HIV-1: Implications for Interpreting Test Results and Retesting After Exposure. Clin Infect Dis 2017; 64:53.</a></li><li><a class="nounderline abstract_t">De Souza MS, Phanuphak N, Pinyakorn S, et al. Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infection. AIDS 2015; 29:793.</a></li><li><a class="nounderline abstract_t">Peters PJ, Westheimer E, Cohen S, et al. Screening Yield of HIV Antigen/Antibody Combination and Pooled HIV RNA Testing for Acute HIV Infection in a High-Prevalence Population. JAMA 2016; 315:682.</a></li><li><a class="nounderline abstract_t">Rosenberg NE, Kamanga G, Phiri S, et al. Detection of acute HIV infection: a field evaluation of the determine® HIV-1/2 Ag/Ab combo test. J Infect Dis 2012; 205:528.</a></li><li><a class="nounderline abstract_t">Kassutto S, Johnston MN, Rosenberg ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 2005; 40:868.</a></li><li><a class="nounderline abstract_t">Hare CB, Pappalardo BL, Busch MP, et al. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis 2006; 42:700.</a></li><li><a class="nounderline abstract_t">Selleri M, Orchi N, Zaniratti MS, et al. Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies. J Acquir Immune Defic Syndr 2007; 46:145.</a></li><li><a class="nounderline abstract_t">Connick E. Incomplete antibody evolution and seroreversion after treatment of primary HIV type 1 infection: what is the clinical significance? Clin Infect Dis 2005; 40:874.</a></li><li><a class="nounderline abstract_t">Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266.</a></li><li><a class="nounderline abstract_t">Yanik EL, Napravnik S, Hurt CB, et al. Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr 2012; 61:258.</a></li><li><a class="nounderline abstract_t">Jain V, Liegler T, Vittinghoff E, et al. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One 2010; 5:e15510.</a></li><li><a class="nounderline abstract_t">Hurt CB, McCoy SI, Kuruc J, et al. Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir Ther 2009; 14:673.</a></li><li><a class="nounderline abstract_t">Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991; 324:961.</a></li><li><a class="nounderline abstract_t">Celum CL, Robinson NJ, Cohen MS. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. J Infect Dis 2005; 191 Suppl 1:S107.</a></li><li><a class="nounderline abstract_t">Colfax GN, Buchbinder SP, Cornelisse PG, et al. Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS 2002; 16:1529.</a></li><li><a class="nounderline abstract_t">Hollingsworth TD, Pilcher CD, Hecht FM, et al. High Transmissibility During Early HIV Infection Among Men Who Have Sex With Men-San Francisco, California. J Infect Dis 2015; 211:1757.</a></li><li><a class="nounderline abstract_t">Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403.</a></li><li><a class="nounderline abstract_t">Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951.</a></li><li><a class="nounderline abstract_t">O'Brien M, Markowitz M. Should we treat acute HIV infection? Curr HIV/AIDS Rep 2012; 9:101.</a></li><li><a class="nounderline abstract_t">Patterson KB, Leone PA, Fiscus SA, et al. Frequent detection of acute HIV infection in pregnant women. AIDS 2007; 21:2303.</a></li></ol></div><div id="topicVersionRevision">Topic 86984 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27192360" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9070472" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19005268" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : HIV-specific regulatory T cells are associated with higher CD4 cell counts in primary infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8245534" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11187417" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25991469" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Frequency and Spectrum of Unexpected Clinical Manifestations of Primary HIV-1 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29228130" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19372938" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical presentation and diagnosis of primary HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17514014" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The relation between symptoms, viral load, and viral load set point in primary HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16586394" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22839749" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Acute HIV-1 infection in the Southeastern United States: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207340" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Acute primary HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2569901" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical course of primary HIV infection: consequences for subsequent course of infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3146367" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical picture of primary HIV infection presenting as a glandular-fever-like illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8678387" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical and epidemiologic features of primary HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1812848" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Primary HIV infection: host responses and intervention strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3563421" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Febrile pharyngitis as the primary sign of HIV infection in a cluster of cases linked by sexual contact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1743707" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical, virological and immunological features of primary HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11361765" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Skin and mucosal characteristics of symptomatic primary HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3404600" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The association between genital ulcer disease and acquisition of HIV infection in homosexual men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2325232" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Acute HIV infection presenting with painful swallowing and esophageal ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3688679" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Acute infection with the human immunodeficiency virus (HIV) associated with acute brachial neuritis and exanthematous rash.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9190500" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Acute pancreatitis during primary HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732147" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hepatitis associated with primary HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16139663" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Fatal brain necrosis in primary HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2998251" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Primary human T-lymphotropic virus type III infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2999591" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28718069" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Neurological involvement in patients with acute/recent HIV-1 infection. A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25110623" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Acute HIV infection presenting as fulminant meningoencephalitis with massive CSF viral replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2866290" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acute encephalopathy coincident with seroconversion for anti-HTLV-III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2885058" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acute myelopathy associated with primary infection with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3468607" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Guillain-Barrésyndrome as an early manifestation of HIV central nervous system infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2831803" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Peripheral neuropathies associated with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2870330" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Acute neuropathy coincident with seroconversion for anti-LAV/HTLV-III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1924033" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Primary HIV-I infection associated with pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2364536" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Lymphocytic alveolitis in primary HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2574381" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Acute rhabdomyolysis coincident with primary HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2252574" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Heparine-like anticoagulant vasculitis associated with severe primary infection by HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8380301" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Acute immunosuppression with HIV seroconversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2905889" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Esophageal candidiasis and immunodeficiency associated with acute HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3171228" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : AIDS two months after primary human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2575913" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Severe clinical manifestations of primary HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8100292" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pneumocystis carinii pneumonia during primary HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7751667" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prolonged cryptosporidiosis during primary HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2966211" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Characterization of T lymphocyte responses during primary infection with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11530029" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10975960" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10975961" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9599194" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9599194" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9599194" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23784012" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm - United States, 2011-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9890848" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9242803" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17205460" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Screening for acute HIV infection: lessons learned.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12004270" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Use of laboratory tests and clinical symptoms for identification of primary HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15872202" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Detection of acute infections during HIV testing in North Carolina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20065201" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846033" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The detection of acute HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12960819" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19535523" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21983253" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22314506" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Testing for acute HIV infection: implications for treatment as prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22207652" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Detection of acute HIV infection: we can't close the window.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27737954" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Time Until Emergence of HIV Test Reactivity Following Infection With HIV-1: Implications for Interpreting Test Results and Retesting After Exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25985402" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26881371" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Screening Yield of HIV Antigen/Antibody Combination and Pooled HIV RNA Testing for Acute HIV Infection in a High-Prevalence Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22207651" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Detection of acute HIV infection: a field evaluation of the determine®HIV-1/2 Ag/Ab combo test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15736021" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16447118" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17589369" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15736022" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Incomplete antibody evolution and seroreversion after treatment of primary HIV type 1 infection: what is the clinical significance?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18549313" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22692092" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21170322" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19704170" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1823118" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15627220" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12131191" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25542958" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : High Transmissibility During Early HIV Infection Among Men Who Have Sex With Men-San Francisco, California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15809897" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17330784" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : High rates of forward transmission events after acute/early HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22415472" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Should we treat acute HIV infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18090278" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Frequent detection of acute HIV infection in pregnant women.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
